HomeFUNDING
FUNDING
Medical device and diagnostics companies are always looking for ways to improve their products and services. In the ever-changing landscape of the healthcare industry, it’s essential for these companies to stay ahead of the curve. That’s why funding is always news.
Series A, B, and other rounds of funding are essential for medical device and diagnostics companies. They provide the necessary capital to help these businesses grow and innovate. And with so many investors interested in this space, there are plenty of opportunities for companies to secure the funding they need.
Syncona: Resolution Therapeutics Raises £63.5 Million in Series B Financing | Appoints New Chair
Use of proceeds from the Series B financing will support the clinical entry and development of RTX001, with a Phase I/II trial expected to start in Q4 CY2024. Following this financing, Resolution Therapeutics is funded to deliver data from this trial, anticipated in CY2026, a key value inflection point with the potential to drive significant NAV growth for Syncona. Proceeds will also be used to develop the company’s manufacturing platform, expand the pre-clinical pipeline, and further strengthen the management team, following several key recent appointments, including Dr Amir Hefni as CEO, Simon Ramsden as CFO and Dr Clifford A. Brass as CMO.
Celaid Therapeutics Inc. Secures up to $19M Grant from the Japanese Agency for Medical Research and Development
Celaid Therapeutics secures up to approx. $19M non-dilutive grant funding from Japanese government. The grant funding will support the development of Celaid's hematopoietic stem cell product for pediatric non-malignant diseases.
Nordic Biotech Company Pila Pharma Raises Capital for New International Obesity Study
According to According to Pila Pharma, the capital raised will support the study with the objective to assess the molecule’s safety in increased dosages, as well as to expand on the number of study participants to determine, though empirical statistical calculations, whether the molecule has potential as part of a new tablet-based obesity treatment., the capital raised will support the study with the objective to assess the molecule’s safety in increased dosages, as well as to expand on the number of study participants to determine, though empirical statistical calculations, whether the molecule has potential as part of a new tablet-based obesity treatment.
Synaptogenix Announces $5.0 Million Financing
"We are pleased to benefit from the support of our committed long-term investors in this financing," said Dr. Alan Tuchman, Chief Executive Officer of Synaptogenix. "This capital enhances our ability to be both strategic and opportunistic as we explore potential acquisitions or fund research on innovative assets, all with the goal of driving growth and maximizing value for our shareholders."
Syantra Secures $4.9 Million in Series A-1 Funding; Adds Dr. Rick Mangat to Board of Directors
Syantra secures new funding for expansion and commercialization of its pioneering platform for early detection of cancer
XII Medical Raises $45 Mil in Series B Financing
To advance best-in-class neuromodulation therapy for obstructive sleep apnea.
Apheros Secures $1.85M
Apheros notes the pre-seed funding round, led by venture capital firm Founderful, will accelerate development and deployment of the companys' revolutionary metal foam-based cooling solutions.
MolecuLight Secures $11.7 Million in Financing to Accelerate Global Expansion
"MolecuLight's innovative technology has the potential to significantly improve patient outcomes and offers compelling benefits for all healthcare system stakeholders," said Guillermo Freire, Senior Vice-President, Mid-Market Group, EDC. "We are excited to invest in MolecuLight as they accelerate commercialization. EDC is focused on supporting emerging Canadian innovators in critical sectors essential for the future. This investment reflects our belief in innovation and progress, underscoring mission is to support Canadian companies in their journey to become international leaders in their sectors."
Prolific Machines Receives Grant to Develop a Platform to Produce Affordable Monoclonal Antibodies to Prevent Infectious Disease in Low- and Middle-Income Countries
Prolific Machines will apply its optogenetics expertise to enable reproducible biomanufacturing solutions that create global access to life-saving drugs for vulnerable populations in low- and middle-income countries (LMICs).